ClinicalTrials.gg
CompletedNCT00562588Updated Mar 19, 2014Results posted

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

A Phase 4 interventional study of Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg) and ASA 100 mg qd in Cerebrovascular Accident, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
551
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies testing aspirin in Stroke — 8 open to participants now, 10 under way, 3 of them phase 3. Aspirin · Stroke.

Enrollment
22nd of 41
551 · median 675
Started
2007
with 3 others
Phase 4
17 of 42
3 open now
Registered
6th of 42
by date
Lead sponsor
1 of 42
Boehringer Ingelheim

Among the 42 studies testing aspirin in Stroke, this one is the 22nd largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2007, is one of 17 in phase 4, and was the 6th registered.

Stroke

8,279 studies on the registry are indexed under Stroke; 2,066 are open to participants now.

Browse Stroke studies →

Open to participants now

8 of the 42 studies testing aspirin in Stroke are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,421 Stroke studies recruiting now, 698 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing aspirin in Stroke, or all of them as a file.
02

Study summary

German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting. They argue that clinical experience with sub-acute Aggrenox treatment is limited and poorly documented when compared with sub-acute acetylsalicylic acid (ASA) treatment. However, long term treatment (started after 3-6 months after stroke/TIA) with Aggrenox was safe and superior to ASA treatment in preventing recurrent strokes. There is no evidence for ASA to prevent from neurological progression after stroke during the first 3 months. Results from a cohort study suggest that starting Aggrenox within 72 hours after stroke predicts clinical improvement in the National Institute of Health Stroke Scale (NIHSS) at discharge from the hospital. Dipyridamole suppresses acute inflammatory responses to stroke.

This study is designed to investigate the tolerability and efficacy of a secondary stroke prevention treatment with Aggrenox when initiated within 24 hours of stroke onset on a stroke unit compared to later initiation after a 7 day ASA treatment and outside off a stroke unit setting.

03

Conditions studied

  • Cerebrovascular Accident

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Clinical diagnosis of ischaemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Symptoms must be distinguishable from an episode of generalised ischaemia (i.e. syncope), seizure, or migraine disorder.

Main inclusion criteria:

  • Patients at risk of stroke who have had transient ischaemia of the brain or completed ischaemic stroke due to thrombosis
  • Symptoms of ischaemic attack began less than 24 hours prior to study medication start, are to be present for at least 30 minutes and have not significantly improved before start of treatment
  • Patients are eligible for inhibiting treatment
  • National Institute of Health Stroke Scale (NIHSS) between 5 and 20 (at pre-screening and screening)
  • Actual Modified Rankin Scale (mRS) (at baseline) is worse than retrospective mRS (before stroke)
  • A for stroke lysis is given
  • Patients are able to give (at least oral) and to swallow either medication

Exclusion criteria

Exclusion Criteria:

  • to any of the components of the product or salicylates.
  • Patients with active gastric or duodenal ulcers or with bleeding disorders.
  • Pregnancy during the third trimester.
  • Lysis therapy.
  • A inhibiting therapy with Acetylsalicylic Acid (ASA) doses of more than 100 mg per day, or with clopidogrel of any dose has been planned or started.
  • Time of onset of stroke symptoms is unknown (when a stroke happened during night-/sleeping time, bedtime is assumed as time of onset)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
551 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Telephone Modified Rankin Scale (Centralised, Blinded Assessment)

    The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)

    Time frame: 90 days

Secondary outcomes

  1. Change From Baseline in NIHSS (National Institutes of Health Stroke Scale)

    The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)

    Time frame: Baseline and 90 days

  2. Patients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding)

    Time frame: 90 days

  3. Telephone Modified Rankin Scale (Centralised, Blinded Assessment) at Day 8

    The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)

    Time frame: 8 days

  4. Change From Baseline in NIHSS (National Institutes of Health Stroke Scale) at Day 8

    The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)

    Time frame: Baseline and 8 days

  5. Change of Special Biochemical Laboratory Value- CRP

    Changes of special biochemical laboratory values (CRP) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory

    Time frame: 8 days

  6. Change of Special Biochemical Laboratory Value- MMP-9

    Changes of special biochemical laboratory value (MMP-9) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory

    Time frame: 8 days

  7. Change of Special Biochemical Laboratory Value - MCP-1

    Changes of special biochemical laboratory value (MCP-1) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory

    Time frame: 8 days

  8. Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 8

    MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).

    Time frame: Baseline and day 8

  9. Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 90.

    MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).

    Time frame: Baseline and day 90

  10. Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 8

    MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.

    Time frame: Baseline and day 8

  11. Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 90

    MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.

    Time frame: Baseline and day 90

07

Results

Posted Mar 11, 2010

Participant flow

551 patients enrolled, 548 randomized, 543 treated; analysis is based on treated patients

Participant flow — Overall Study
MilestoneAspirin for 7 Days, Followed by AggrenoxAggrenox
Started260283
Completed168184
Not completed9299
Withdrew: Adverse event4058
Withdrew: Protocol violation3026
Withdrew: Lost to follow-up124
Withdrew: Withdrawal by subject109
Withdrew: Other02

Outcome measures

PrimaryTelephone Modified Rankin Scale (Centralised, Blinded Assessment)

The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)

Time frame:
90 days
Reported as:
Number · participants
Telephone Modified Rankin Scale (Centralised, Blinded Assessment)
participantsAspirin for 7 Days, Followed by AggrenoxAggrenox
05870
17584
25062
33016
43132
564
645
Statistical analysis
  • Aspirin for 7 Days, Followed by Aggrenox vs Aggrenox · Regression, Logistic · p = 0.683 · Odds ratio (or): 1.067 · 95% CI 0.78 to 1.461
SecondaryChange From Baseline in NIHSS (National Institutes of Health Stroke Scale)

The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)

Time frame:
Baseline and 90 days
Reported as:
Median · Units on a scale
Change From Baseline in NIHSS (National Institutes of Health Stroke Scale)
Units on a scaleAspirin for 7 Days, Followed by AggrenoxAggrenox
Change From Baseline in NIHSS (National Institutes of Health Stroke Scale)-2 (-4 to 0)-2 (-3 to 0)
Statistical analysis
  • Aspirin for 7 Days, Followed by Aggrenox vs Aggrenox · ANCOVA · p = 0.607ANCOVA with factors for treatment, age, weight, baseline SBP, diabetes, previous stroke and baseline NIHSS
SecondaryPatients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding)
Time frame:
90 days
Reported as:
Number · participants
Patients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding)
participantsAspirin for 7 Days, Followed by AggrenoxAggrenox
Patients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding)3828
Statistical analysis
  • Aspirin for 7 Days, Followed by Aggrenox vs Aggrenox · Cox proportional hazards model · p = 0.202 · Hazard ratio (hr): 0.725 · 95% CI 0.442 to 1.189
SecondaryTelephone Modified Rankin Scale (Centralised, Blinded Assessment) at Day 8

The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)

Time frame:
8 days
Reported as:
Number · participants
Telephone Modified Rankin Scale (Centralised, Blinded Assessment) at Day 8
participantsAspirin for 7 Days, Followed by AggrenoxAggrenox
04647
15974
24252
33938
45144
5128
602
Missing58
SecondaryChange From Baseline in NIHSS (National Institutes of Health Stroke Scale) at Day 8

The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)

Time frame:
Baseline and 8 days
Reported as:
Median · units on a scale
Change From Baseline in NIHSS (National Institutes of Health Stroke Scale) at Day 8
units on a scaleAspirin for 7 Days, Followed by AggrenoxAggrenox
Change From Baseline in NIHSS (National Institutes of Health Stroke Scale) at Day 8-1.0 (-3.0 to 0.0)-1.0 (-3.0 to 0.0)
SecondaryChange of Special Biochemical Laboratory Value- CRP

Changes of special biochemical laboratory values (CRP) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory

Time frame:
8 days
Reported as:
Geometric mean · mg/L
Change of Special Biochemical Laboratory Value- CRP
mg/LAspirin for 7 Days, Followed by AggrenoxAggrenox
Change of Special Biochemical Laboratory Value- CRP1.27 (1.06 to 1.52)1.17 (1.00 to 1.38)
SecondaryChange of Special Biochemical Laboratory Value- MMP-9

Changes of special biochemical laboratory value (MMP-9) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory

Time frame:
8 days
Reported as:
Geometric mean · ng/mL
Change of Special Biochemical Laboratory Value- MMP-9
ng/mLAspirin for 7 Days, Followed by AggrenoxAggrenox
Change of Special Biochemical Laboratory Value- MMP-90.974 (0.884 to 1.07)0.983 (0.89 to 1.08)
SecondaryChange of Special Biochemical Laboratory Value - MCP-1

Changes of special biochemical laboratory value (MCP-1) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory

Time frame:
8 days
Reported as:
Geometric mean · µg/mL
Change of Special Biochemical Laboratory Value - MCP-1
µg/mLAspirin for 7 Days, Followed by AggrenoxAggrenox
Change of Special Biochemical Laboratory Value - MCP-11.06 (1.01 to 1.10)1.08 (1.03 to 1.13)
SecondaryChange From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 8

MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).

Time frame:
Baseline and day 8
Reported as:
Median · mL
Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 8
mLAspirin for 7 Days, Followed by AggrenoxAggrenox
Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 80.4100 (0.1050 to 2.0450)0.3300 (0.0200 to 1.3500)
SecondaryChange From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 90.

MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).

Time frame:
Baseline and day 90
Reported as:
Median · mL
Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 90.
mLAspirin for 7 Days, Followed by AggrenoxAggrenox
Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 90.0.1900 (0.0000 to 1.1400)0.1150 (0.0000 to 0.9000)
SecondaryChange From Baseline in DWI (Diffuse-Weighted Imaging) at Day 8

MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.

Time frame:
Baseline and day 8
Reported as:
Median · mL
Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 8
mLAspirin for 7 Days, Followed by AggrenoxAggrenox
Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 8-0.0600 (-0.7050 to 0.5650)0.0000 (-0.5000 to 0.3000)
SecondaryChange From Baseline in DWI (Diffuse-Weighted Imaging) at Day 90

MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.

Time frame:
Baseline and day 90
Reported as:
Median · mL
Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 90
mLAspirin for 7 Days, Followed by AggrenoxAggrenox
Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 90-0.8400 (-2.0850 to -0.3550)-0.7100 (-1.9300 to -0.2600)

Adverse events

Collected over Up to 90 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aspirin for 7 Days, Followed by Aggrenox—48/260 (18.5%)60/260 (23.1%)
Aggrenox—45/283 (15.9%)119/283 (42%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventAspirin for 7 Days, Followed by AggrenoxAggrenox
Cerebrovascular accidentNervous system disorders15/2605/283
Carotid artery stenosisNervous system disorders5/2602/283
Transient ischaemic attackNervous system disorders4/2602/283
Myocardial infarctionCardiac disorders1/2604/283
Ischaemic strokeNervous system disorders3/2601/283
PneumoniaInfections and infestations3/2600/283
Atrial septal defectCongenital, familial and genetic disorders3/2603/283
Atrial fibrillationCardiac disorders2/2603/283
Cardiac failureCardiac disorders1/2603/283
DepressionPsychiatric disorders2/2601/283
Most frequent other events
Most frequent other events
EventAspirin for 7 Days, Followed by AggrenoxAggrenox
HeadacheNervous system disorders53/260105/283
NauseaGastrointestinal disorders14/26029/283
VomitingGastrointestinal disorders10/26026/283

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aspirin for 7 Days, Followed by AggrenoxAggrenoxTotal
Mean68.3 ± 11.566.5 ± 11.467.3 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Aspirin for 7 Days, Followed by AggrenoxAggrenoxTotal
Female95109204
Male165174339
08

Study locations

1 site
  • 9.182.1 Boehringer Ingelheim Investigational Site
    Bad Homburg, Germany
09

References and documents

Publications

  • Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, Eschenfelder CC, Leonard J, Weissenborn K, Kastrup A, Haberl R; EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010 Feb;9(2):159-66. doi: 10.1016/S1474-4422(09)70361-8. Epub 2010 Jan 7. PubMed 20060783 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2007
First posted
Nov 22, 2007
Start
Jul 2007
Primary completionActual
Feb 2009
Results first posted
Mar 11, 2010
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00562588
First posted
Nov 22, 2007
Start date
Jul 2007
Primary completion
Feb 2009
Results posted
Mar 11, 2010
Last update
Mar 19, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion